(Q39605867)

13 September 2017

title

The therapeutic potential of SA-sCD40L in the orthotopic model of superficial bladder cancer (English)

1 reference

13 September 2017

Zhen Zhang

1

1 reference

13 September 2017

Xiaoling Xu

2

1 reference

13 September 2017

Xiaoren Zhang

3

1 reference

13 September 2017

Xiqian Chen

4

1 reference

13 September 2017

Qingge Chen

5

1 reference

13 September 2017

Lina Dong

6

1 reference

13 September 2017

Zhiming Hu

7

1 reference

13 September 2017

Jinlong Li

8

1 reference

13 September 2017

Jimin Gao

9

1 reference

13 September 2017

publication date

19 January 2011

1 reference

13 September 2017

1 reference

13 September 2017

volume

50

1 reference

13 September 2017

issue

7

1 reference

13 September 2017

page(s)

1111-1118

1 reference

Superficial bladder cancer: the role of interferon-alpha.

13 September 2017

cites work

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2010.549838

Pharmacotherapy of bladder cancer--practice and prospects

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2010.549838

AdCD40L gene therapy counteracts T regulatory cells and cures aggressive tumors in an orthotopic bladder cancer model

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2010.549838

Antitumor responses induced by transgenic expression of CD40 ligand

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2010.549838

Adenovirus-mediated CD40 ligand therapy induces tumor cell apoptosis and systemic immunity in the TRAMP-C2 mouse prostate cancer model.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2010.549838

CD40 stimulation leads to effective therapy of CD40(-) tumors through induction of strong systemic cytotoxic T lymphocyte immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2010.549838

A novel function of CD40: induction of cell death in transformed cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2010.549838

CD40-CD40 ligand (CD154) engagement is required but not sufficient for modulating MHC class I, ICAM-1 and Fas expression and proliferation of human non-small cell lung tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2010.549838

A new mechanism of NK cell cytotoxicity activation: the CD40-CD40 ligand interaction.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2010.549838

Molecular mechanism and function of CD40/CD40L engagement in the immune system.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2010.549838

Recombinant soluble trimeric CD40 ligand is biologically active

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2010.549838

GM-CSF-surface-modified B16.F10 melanoma cell vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2010.549838

Optimization of the MB49 mouse bladder cancer model for adenoviral gene therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2010.549838

A novel immunotherapy for superficial bladder cancer by intravesical immobilization of GM-CSF.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2010.549838

10.3109/0284186X.2010.549838

21 January 2018

Identifiers

DOI

1 reference

13 September 2017

1 reference